Zydus Lifesciences的利润净额在2025年的Q3中增长了1.8%,达到1,042克朗,印度、美国和国际市场收入增长30%,业绩强劲。 Zydus Lifesciences saw net profit rise 1.8% to ₹1,042 crore in Q3 2025, fueled by 30% revenue growth and strong performance in India, the U.S., and international markets.

Zydus LifeSciences报告,2025年12月终了第三季度净利润增长了1.8%,达到1 042克朗,收入猛增30%,达到6 864克朗,其驱动力是印度、美国和国际市场的强劲增长。 Zydus Lifesciences reported a 1.8% rise in net profit to ₹1,042 crore for the third quarter ending December 2025, with revenue surging 30% to ₹6,864 crore, driven by strong growth in India, the U.S., and international markets. 该公司北美收入增长16.4%,印度增长13%,国际销售增长38%,得到新产品发行的支持,包括林业发展局批准Zycubo,这是对门克斯病的首次治疗。 The company saw a 16.4% increase in North America revenue, a 13% rise in India, and a 38% jump in international sales, supported by new product launches, including FDA approval for Zycubo, the first treatment for Menkes disease. EBITDA增加了31%,达到1,816克朗,利润率提高到26.5%。 EBITDA rose 31% to ₹1,816 crore, with margins improving to 26.5%. 尽管运营成本(包括一次性劳动法规定)较高,但该公司保持盈利,并宣布在生物类和收购方面取得进展。 Despite higher operating costs, including a one-time labor code provision, the company maintained profitability and announced progress in biosimilars and acquisitions.